RPIDHealthcare · Medical DevicesThe 5 Wall Street analysts covering Rapid Micro Biosystems, Inc. hold a median 12-month price target of $6 — +660.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 26 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Rapid Micro Biosystems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on RPID, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +660.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Roth Capital | Initiates | Buy | $3.00 |
| 29 May 2026 | Keybanc | Maintains | Overweight | $8.00 → $5.00 |
| 29 May 2026 | Keybanc | Maintains | Overweight | — |
| 22 May 2026 | Lake Street | Maintains | Buy | $8.00 → $7.00 |
| 22 May 2026 | Lake Street | Maintains | Buy | — |
| 28 July 2025 | Lake Street | Initiates | Buy | — |
| 12 Feb 2025 | Keybanc | Initiates | Overweight | — |
| 7 Mar 2023 | Morgan Stanley | Reiterates | Equal-Weight | — |
| 16 Aug 2022 | JP Morgan | Downgrade | Neutral | — |
| 11 May 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Nov 2021 | Morgan Stanley | Maintains | Equal-Weight | — |
| 9 Aug 2021 | Cowen & Co. | Initiates | Outperform | — |
| 9 Aug 2021 | JP Morgan | Initiates | Overweight | — |
| 9 Aug 2021 | Morgan Stanley | Initiates | Equal-Weight | — |
| 9 Aug 2021 | Stifel | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RPID appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Rapid Micro Biosystems, Inc. returned −72.5% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 82% of US stocks
Cheaper than 65% of US stocks
Cheaper than 39% of US stocks
Cheaper than 68% of US stocks
Higher than 55% of US stocks
Higher than 50% of US stocks
Higher than 14% of US stocks
Higher than 12% of US stocks
Higher than 4% of US stocks
Higher than 10% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rapid Micro Biosystems, Inc. has a market value of $40.1M and an enterprise value of $43.1M.
Revenue in the twelve months to 30 June 2026: $35.2M. The latest quarter grew 10.9% year on year.
Net income over the same four quarters: −$51.2M, a −145.6% net margin.
Diluted earnings per share, trailing twelve months: $−1.12.
Free cash flow in the twelve months to 30 June 2026: −$40.4M.
Trailing P/E: −0.8×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Rapid Micro Biosystems, Inc. employs 171 people — $206K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Rapid Micro Biosystems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Rapid Micro Biosystems announced it will participate as a sponsor of the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C.
Why it matters — The announcement provides RPID watchers with information about the company’s conference participation.
Rapid Micro Biosystems, Inc. announced that it plans to participate in several upcoming investor conferences. The company, which provides automation solutions for healthcare product manufacturing, shared this through a press release from its Lexington, Massachusetts headquarters.
Why it matters — RPID watchers would be interested since investor conference participation offers management the opportunity to present the company's strategy and operations to the investment community, making it a routine but notable corporate activity.
Rapid Micro Biosystems (RPID) is described as technically oversold after falling 33.7% over four weeks. The article notes that analysts have been revising earnings estimates upward, which together suggests a possible near-term trend reversal for the stock.
Why it matters — A RPID watcher would care because the combination of oversold technical conditions and upward earnings estimate revisions could signal that the stock's recent decline may be coming to an end.
Rapid Micro Biosystems (RPID) shares have fallen 25.7% over the past four weeks and are now technically in oversold territory. Wall Street analysts show strong agreement in revising earnings estimates upward, which the piece suggests could signal a trend reversal.
Why it matters — RPID watchers would care because the combination of an oversold technical reading and upward analyst estimate revisions could indicate a shift in the stock's recent downward trajectory.
Rapid Micro Biosystems (RPID) was upgraded to a Zacks Rank #2 (Buy). The upgrade reflects growing optimism about the company's earnings prospects.
Why it matters — The upgrade signals a change in analyst sentiment toward RPID's earnings outlook that watchers of the stock may find notable.
The 5 Wall Street analysts covering Rapid Micro Biosystems, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering Rapid Micro Biosystems, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapid Micro Biosystems, Inc. 26 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Rapid Micro Biosystems, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +660.5% from the last close, and Ticker Nerd's factor model ranks Rapid Micro Biosystems, Inc. 26 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Rapid Micro Biosystems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8 over the next 12 months.
Rapid Micro Biosystems, Inc. returned -72.5% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries.
The most recent item we track (GlobeNewsWire, 20 Oct 2026): "Rapid Micro Biosystems to Participate at the PDA Pharmaceutical Microbiology Conference 2026". Rapid Micro Biosystems announced it will participate as a sponsor of the PDA Pharmaceutical Microbiology Conference 2026 in Washington, D.C.
Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries. The company develops mission-critical solutions that help manufacturers detect microbial contamination and support the efficient manufacturing and safe release of healthcare products. Its current offerings include the Growth Direct platform, which combines an automated system, proprietary consumables, software for laboratory information management system connectivity, and validation and support services. These products are used across regulated environments involved in biologics, vaccines, cell and gene therapies, sterile injectables, medical devices, and personal care products. Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems serves customers in the United States and international markets, where faster and more reliable microbial testing plays an important role in modern production workflows.
CEO Mr. Robert G. Spignesi Jr. · 171 employees · United States · https://www.rapidmicrobio.com
